These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

638 related items for PubMed ID: 26795735

  • 1. Cross-talk between two antioxidants, thioredoxin reductase and heme oxygenase-1, and therapeutic implications for multiple myeloma.
    Raninga PV, Di Trapani G, Vuckovic S, Tonissen KF.
    Redox Biol; 2016 Aug; 8():175-85. PubMed ID: 26795735
    [Abstract] [Full Text] [Related]

  • 2. TrxR1 inhibition overcomes both hypoxia-induced and acquired bortezomib resistance in multiple myeloma through NF-кβ inhibition.
    Raninga PV, Di Trapani G, Vuckovic S, Tonissen KF.
    Cell Cycle; 2016 Aug; 15(4):559-72. PubMed ID: 26743692
    [Abstract] [Full Text] [Related]

  • 3. Heme oxygenase-1 inhibition mediates Gas6 to enhance bortezomib-sensitivity in multiple myeloma via ERK/STAT3 axis.
    Zhang Z, Wang W, Ma D, Xiong J, Kuang X, Zhang S, Fang Q, Wang J.
    Aging (Albany NY); 2020 Apr 16; 12(8):6611-6629. PubMed ID: 32298237
    [Abstract] [Full Text] [Related]

  • 4. Heme oxygenase-1 nuclear translocation regulates bortezomibinduced cytotoxicity and mediates genomic instability in myeloma cells.
    Tibullo D, Barbagallo I, Giallongo C, Vanella L, Conticello C, Romano A, Saccone S, Godos J, Di Raimondo F, Li Volti G.
    Oncotarget; 2016 May 17; 7(20):28868-80. PubMed ID: 26930712
    [Abstract] [Full Text] [Related]

  • 5. Anticancer activity of a Gold(I) phosphine thioredoxin reductase inhibitor in multiple myeloma.
    Sze JH, Raninga PV, Nakamura K, Casey M, Khanna KK, Berners-Price SJ, Di Trapani G, Tonissen KF.
    Redox Biol; 2020 Jan 17; 28():101310. PubMed ID: 31514052
    [Abstract] [Full Text] [Related]

  • 6. Selective inhibition of endogenous antioxidants with Auranofin causes mitochondrial oxidative stress which can be countered by selenium supplementation.
    Radenkovic F, Holland O, Vanderlelie JJ, Perkins AV.
    Biochem Pharmacol; 2017 Dec 15; 146():42-52. PubMed ID: 28947276
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Inhibition of thioredoxin reductase by auranofin induces apoptosis in adriamycin-resistant human K562 chronic myeloid leukemia cells.
    Liu JJ, Liu Q, Wei HL, Yi J, Zhao HS, Gao LP.
    Pharmazie; 2011 Jun 15; 66(6):440-4. PubMed ID: 21699084
    [Abstract] [Full Text] [Related]

  • 9. Auranofin radiosensitizes tumor cells through targeting thioredoxin reductase and resulting overproduction of reactive oxygen species.
    Wang H, Bouzakoura S, de Mey S, Jiang H, Law K, Dufait I, Corbet C, Verovski V, Gevaert T, Feron O, Van den Berge D, Storme G, De Ridder M.
    Oncotarget; 2017 May 30; 8(22):35728-35742. PubMed ID: 28415723
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Potential crosstalk of the interleukin-6-heme oxygenase-1-dependent mechanism involved in resistance to lenalidomide in multiple myeloma cells.
    Wu W, Ma D, Wang P, Cao L, Lu T, Fang Q, Zhao J, Wang J.
    FEBS J; 2016 Mar 30; 283(5):834-49. PubMed ID: 26700310
    [Abstract] [Full Text] [Related]

  • 14. Bortezomib induces heme oxygenase-1 expression in multiple myeloma.
    Barrera LN, Rushworth SA, Bowles KM, MacEwan DJ.
    Cell Cycle; 2012 Jun 15; 11(12):2248-52. PubMed ID: 22617388
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Thioredoxin Reductase Inhibition Attenuates Neonatal Hyperoxic Lung Injury and Enhances Nuclear Factor E2-Related Factor 2 Activation.
    Li Q, Wall SB, Ren C, Velten M, Hill CL, Locy ML, Rogers LK, Tipple TE.
    Am J Respir Cell Mol Biol; 2016 Sep 15; 55(3):419-28. PubMed ID: 27089175
    [Abstract] [Full Text] [Related]

  • 17. Potential Anticancer Activity of Auranofin.
    Onodera T, Momose I, Kawada M.
    Chem Pharm Bull (Tokyo); 2019 Sep 15; 67(3):186-191. PubMed ID: 30827998
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Targeted knockdown of DJ-1 induces multiple myeloma cell death via KLF6 upregulation.
    Raninga PV, Di Trapani G, Vuckovic S, Tonissen KF.
    Apoptosis; 2016 Dec 15; 21(12):1422-1437. PubMed ID: 27734217
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.